Baxter (BAX) Offering Possible 12.36% Return Over the Next 30 Calendar Days

Baxter's most recent trend suggests a bullish bias. One trading opportunity on Baxter is a Bull Put Spread using a strike $80.00 short put and a strike $75.00 long put offers a potential 12.36% return on risk over the next 30 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $80.00 by expiration. The full premium credit of $0.55 would be kept by the premium seller. The risk of $4.45 would be incurred if the stock dropped below the $75.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Baxter is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Baxter is bullish.

The RSI indicator is at 34.97 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Baxter

Baxter (BAX) Receives EUA for Regiocit Replacement Solution
Mon, 17 Aug 2020 10:06:10 +0000
Baxter (BAX) receives EUA from the FDA for Regiocit, which is the only authorized citrate-based replacement solution for use in CRRT during the COVID-19 pandemic.

Baxter Gets FDA Emergency Use Nod For Regiocit During Covid-19 Pandemic
Sun, 16 Aug 2020 06:34:36 +0000
Baxter International has been granted Emergency Use Authorization (EUA) by the US Food and Drug Administration (FDA) for its Regiocit, to be used during the coronavirus pandemic as a replacement solution only in adult patients suffering from acute kidney injury.Baxter (BAX) said that under the EUA, Regiocit is now authorized to be used in adult patients being treated with continuous renal replacement therapy (CRRT) and for whom regional citrate anticoagulation is appropriate during the COVID-19 pandemic.Acute kidney injury, a potentially life-threatening condition where the kidneys suddenly stop working and fluid and uremic toxins build up in the body, is one of many complications affecting COVID-19 patients. CRRT mimics many of the functions of the natural kidney and is the cornerstone of treatment in patients with severe acute kidney injury. Regiocitis the only authorized citrate-based replacement solution available in the US for use in CRRT during the COVID-19 pandemic, Baxter said.“Demand for CRRT remains elevated as the COVID-19 pandemic continues to progress, and we’re proud to offer Regiocitas an important new option to help healthcare providers in the US optimize care for critically ill patients requiring CRRT and regional citrate anticoagulation, while bringing an additional supply of replacement solutions to the US,” said Reaz Rasul, general manager of Baxter’s Acute Therapies business.Regiocitcontains physiological concentrations of sodium (140 mmol/l), chloride (86 mmol/l) and a low concentration of citrate (18 mmol/L) and can provide the necessary pre-filter volumes required to replace filtration losses during convective therapies. It is used in combination with other standard dialysis and replacement solutions that supplement missing electrolytes such as potassium, magnesium and phosphate.Deerfield, Illinois-based Baxter added that it continues to provide CRRT machines, fluids and sets to help healthcare facilities address patient needs around the world.Regiocit has not been approved by the FDA in the US but is currently in use in countries around the world, including in Europe and Asia. A limited initial shipment will be available in the US immediately, with more significant production ramping up throughout the coming weeks and months, the company said.Baxter shares advanced 1.6% in Friday’s after-market session and are now trading little changed from their start of the year level. The $96.14 average analyst price target indicates 15% upside potential in the shares over the coming 12 months.Credit Suisse analyst Matt Miksic last week reiterated a Buy rating on the stock with a $99 price target, saying that he views the stock as attractive at current levels, trading significantly below its 3-year average multiple relative to the S&P 500.“Strength in Acute Therapies is expected to continue, driven mostly by consumable growth and utilization related to COVID-19, with some deceleration in 2H vs. 1H,” Miksic wrote in a note to investors.Overall Wall Street analysts share Miksic’s bullish outlook. The Strong Buy consensus boasts 6 Buys versus 3 Holds. (See Baxter stock analysis on TipRanks)Related News: Novavax Pops 7% On South Korea Deal For Global Covid-19 Vaccine Supply EU Secures 200M Doses Of Johnson & Johnson’s Covid-19 Vaccine Candidate Quidel’s Lyra Covid-19 Test Gets Nod For Sale In Canada; Shares Rise 6% More recent articles from Smarter Analyst: * Alibaba’s Ant Group Starts Filing Process For Blockbuster China IPO * Buffett’s Berkshire Builds Position In Barrick Gold, Says Goodbye To US Banks * Barclays Cuts Micron's PT On Chip Demand Woes * Baidu Takes Buyback Program To $3B; Stock Down 6% Post-Print

Baxter Obtains U.S. FDA Emergency Use Authorization for Regiocit Replacement Solution Used in CRRT
Fri, 14 Aug 2020 21:00:00 +0000
Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for Regiocit, the company’s replacement solution that contains citrate for regional citrate anticoagulation of the extracorporeal circuit. Under the EUA, Regiocit is authorized to be used as a replacement solution only in adult patients being treated with continuous renal replacement therapy (CRRT) and for whom regional citrate anticoagulation is appropriate during the COVID-19 pandemic.

Baxter Obtains U.S. FDA Emergency Use Authorizations for HF20 Set and ST Set Used in CRRT During Covid-19 Pandemic
Wed, 12 Aug 2020 13:00:00 +0000
Baxter International Inc. (NYSE:BAX), a global leader in acute care, announced it has received Emergency Use Authorizations (EUAs) from the U.S. Food and Drug Administration (FDA) for the company’s HF20 Set and ST Set used in continuous renal replacement therapy (CRRT). Under its EUA, the HF20 Set is authorized to deliver CRRT to treat patients of low weight (8-20 kg) and low blood volume who cannot tolerate a larger extracorporeal circuit volume in an acute care environment during the COVID-19 pandemic. The ST Set is authorized for use under its EUA to provide CRRT to treat patients in an acute care environment during the COVID-19 pandemic. Both the HF20 Set and ST Set can be used with the Prismaflex or PrisMax control units (monitors).

Baxter Introduces Virtual Peritoneal Dialysis Excellence Academy for Nurses in the U.S.
Wed, 05 Aug 2020 12:30:00 +0000
Baxter International, Inc. (NYSE:BAX), a global innovator in renal care, announced today the launch of the PD Excellence Academy, a new virtual training platform and educational resource center to help nurses develop their PD skills to deliver optimal patient care. The platform also offers a benefit to employers, including dialysis clinic administrators and nephrologists, who now have an additional resource available to develop and retain talent. As home dialysis rates continue to rise, so does the demand for nurses who have the expertise to successfully manage a PD program.

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.